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ABSTRACT 
Background: Thyroid malignancy is one of the most common malignancies in 
women of reproductive age. One of the normal physiological change in pregnancy is 
an increase in total maternal thyroid levels. According to 2015 DATIN information, 
the prevalence of hypothyroidism in women of reproductive age was 2.2%. Method 
of delivery in patients with thyroid disorders are mostly by cesarean section due to 
complications of the mother and/or fetus. Fetal outcome usually associated with low 
birth weight and poor APGAR Score. 
Objective: Reporting a case of pregnancy with hypothyroidism secondary to 
thyroid carcinoma treatment  
Case Presentation: 37-year-old woman Gravida 3 Parity 2 Abortion 0 with 18 
weeks pregnancy after thyroid ablation treatment with a history of Papillary Thyroid 
Carcinoma – Follicular Variant, following a complete thyroidectomy in August 2016. 
The patient was given 6-dose ablation therapy, the last therapy was performed in 
April 2019. On clinical examination, the patient have no sign and symptoms 
suggesting hypothyroidism. On laboratory examination, the thyroid stimulating 
hormone (TSH) level was increased. Levothyroxine dosage was adjusted until the 
patient in euthyroid status in the early 3rd trimester of pregnancy until the delivery 
period. The fetal examination suggests that the Bio-Physical Profile was normal 
according to gestational age. The patient underwent vaginal delivery following 38 
weeks of gestation with good maternal outcomes and low birth weight neonatal 
outcomes, no thyroid nodules, and slightly increased thyroid function. 
Conclusion: Management of counselling about preconception, contraception, and 
initial screening of patients with a history of thyroid carcinoma are the initial steps to 
help a better outcome in pregnancies with thyroid disorders. 
 






Thyroid Disorders is a metabolic disease with 
the second highest incidence rate after Diabetes 
Mellitus in Indonesia. According to information 
from DATIN (Centre for Data and Information of 
the Indonesian Ministry of Health) in 2015, the 
prevalence of hypothyroidism in women of 
reproductive age was 2.2%.1 Thyroid Carcinoma 
subtype Follicular Variant Papillary Carcinoma is a 
case that is more common in women of reproductive 
age.2 One of the changes in the normal physiology of 
pregnancy is slightly increased amount of maternal 
thyroid levels. The method of delivery in patients 
with thyroid disorders are mostly by caesarean 
section due to complications of the mother and/or 
fetus. Fetal outcome usually associated with low 
birth weight and poor APGAR Score. 
In this case, we present a case of pregnancy with 
a history of thyroid carcinoma who had completed 
radio-nuclear treatment 3 months before conception 
with a hypothyroid state during pregnancy. The baby 
was conceiver naturally, had a full-term pregnancy 
and undergone vaginal delivery with good maternal 
outcomes and low birth weight baby, good APGAR 
Score, and no signs of congenital hypothyroidism. 
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2. Case Presentation 
A 37 years old female, Gravida 3 Parity 2 
Abortion 0, working as a housewife, was found 18 
weeks pregnant 3 months after sixth thyroid ablation 
at the time of examination. The patient had a history 
of Papillary Thyroid Carcinoma Follicular Variant 
type of thyroid carcinoma and a complete 
thyroidectomy performed in August 2016. The 
patient was then given ablation therapy 6 times until 
April 2019. At 3 months of preconception, high 
thyroid stimulating hormone (TSH) levels reached 
150 mIU/L. (Fig. 1) Patients routinely consumed 
levothyroxine 50 mg once a day and calcium 
bicarbonate 500 mg three times a day by prescriptions 
from an oncologist. In the course of pregnancy, 
Thyroid Stimulating Hormone (TSH) increases so 
that the levothyroxine dose was adjusted 100 mg at 
26 weeks of gestation until the patient was in 
euthyroid status in the early 3rd trimester of 
pregnancy to the time of delivery. (Fig. 2) 
On physical examination, the general findings 
was good, no complaints of fatigue, normal vital 
signs, hair loss, dry skin, nodules on the neck, nor 
significant weight gain that was more than normal in 
pregnancy. The blood laboratory test results are 
normal, where the TSH value varies as stated below 








During the Antenatal Care Visit (ANC) at 18 
weeks of gestation, the results of the ultrasound 
examination showed normal fetal growth in 
accordance with the gestational age with an estimated 
fetal weight of 237 grams, the amount of amniotic 
fluid with a Maximal Vertical Pocket of 3.47 cm, 
normal placenta implantation and no fetal 
abnormalities were to be seen. 
During the antenatal visit at 26 weeks' gestation, 
the results of the fetal growth ultrasound examination 
were consistent with gestational age with estimated 
weight of 751.44 grams. No fetal abnormalities were 
seen on the tests performed. 
On 14 June 2020 the patient presented at 38 
weeks of gestation with timely contractions and was 
planned for vaginal delivery. The following day, 
patient gave birth spontaneously to a baby boy 
weighed 2455 grams, with favourable APGAR score 
of 9-10-10. On the physical examination of the new-
born, there was no nodule on the neck, with the 
impression of a vigorous baby. During their treatment 
at the hospital, the neonates receive exclusive 
breastfeeding and was screened for thyroid levels on 
the third day following birth, with a high TSH result 
of 8.58 (normal value: 0.51-4.94) and Free T4 (FT4) 
25.63 (normal value: 10.6 - 19.4). 
3. Discussion 
In early pregnancy, thyroid hormone increases 
in the presence of oestrogen stimulation, thereby 
increasing the distribution of thyroid hormones in the 
form of Free T3 (FT3) and FT4 which can cross the 
placental blood barrier, while TSH from the mother 
does not penetrate the placental barrier, so the 
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Figure 1. The results of the TSH level examination from the 
timeframe carried out the last ablation (April 2019) until 
before conception. 
Figure 2.TSH levels from the beginning of conception (July 
2019) to the end of pregnancy (May 2020) 
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accurate measurement methods during pregnancy. 
Meanwhile, during pregnancy, because the TSH 
receptors in the body compete with the alpha subunit 
of HCG, the normal reference level during pregnancy 
tends to be lower than non-pregnant state. Normal 
TSH levels in non-pregnant women are 0.3-4.3, 
whereas at the time of pregnancy, the normal values 
in 1st Trimester is 0.1-2.5, 2nd Trimester is 0.2-3.0, 
and in 3rd Trimester is 0.3-3.0.2,3 
Hypothyroidism can be divided into 2 
classifications, clinical hypothyroidism and 
subclinical hypothyroidism. Clinical hypothyroidism 
is defined as a deficiency in thyroid hormone, 
diagnosed by high TSH levels accompanied by low 
FT4 with significant clinical symptoms in the patient. 
Pregnancy with hypothyroidism can have 
several effects on the mother and fetus, including the 
increased risk of miscarriage, preeclampsia or 
gestational hypertension, anemia, prematurity, and an 
increased incidence of postpartum morbidity and 
mortality such as postpartum hemorrhage, and 
thyroid dysfunction over a long period of time. The 
effect on the fetus is that it can inhibit development 
and growth as well as neurocognitive decline in 
children.4,5 Adequate iodine intake and maternal T3 
T4 levels are the main determinants of the 
equilibrium state of thyroid development in the 
fetus.6 
This case reported the condition of a 
hypothyroid mother in the preconception period until 
the end of the second trimester of pregnancy. This is 
expressed by the high level of TSHs = 150.0, where 
the normal threshold for non-pregnant women is 4.3. 
This situation is secondary to the operative treatment 
of thyroid malignancy and iodine ablation as the 
management of malignant cases of thyroid carcinoma 
thus causing hypothyroid state despite hormone 
replacement therapy with levothyroxine. In spite of 
having no plans to conceive again, patient had never 
been counselled for contraceptive use at the time of 
operative treatment and during ablation therapy. 
Patients regularly visit the Nuclear Medicine Clinic 
for ablation therapy and TSH and calcium levels are 
monitored monthly. Patients received iodine ablation 
therapy according to the NCCN (National 
Comprehensive Cancer Network) are advised to 
postpone pregnancy for approximately 6 months after 
the last ablation therapy and to conduct 
preconception counselling to confirm thyroid status 
before pregnancy.5,7 This is based on several studies 
that have proven that the hypothyroidism of the 
mother from the time of conception to the early 
trimester of pregnancy will impact vastly on fetal 
development process, thus also contributing to 
mental and cognitive development of the baby after 
birth. 
According to Sreelatha S et al. in mothers with 
hypothyroidism, there were 1.9% cases of infants 
with low birth weight, 9.4% cases of infants with 
hyperbilirubinemia and 14.6% of infants admitted to 
the Neonatal Intensive Care Unit (NICU). It was 
found that normal TSH levels were found in almost 
all infants, only 4 cases of hyperthyroidism where 
only one patient suffered from anemia and 
oligohydramion. 
According to Sima Nazarpour et al. the long-
term effects of clinical hypothyroidism on cognitive 
function are well documented, with children born to 
mothers with clinical hypothyroidism showing 
developmental disorders. 
There was an increase in FT4 in newborns up to 
12 weeks of age and began to decline until finally 
reached normal limits in over 12 weeks of age. FT4 
levels were also found to be slightly increased in male 
babies than in female babies. The fetal outcome in 
this case a male infant with low birth weight, 2455 
grams, with inconclusive laboratory conditions. The 
new-born still showed inconclusie state from 
laboratory results of high TSH 8.58 (normal values: 
0.51–4.94) and FT4 25.63 (normal values: 10.6–
19.4). This is possible because there are still FT3 and 
FT4 from the mother who were present in fetal blood. 
The determination of hypo and hyper-thyroid status 
in neonates was carried out after 14 days of birth 
where it was assumed that there was no more thyroid 
hormone from the mother's body in the new-born. No 
congenital thyroid abnormalities was found in the 
new-born and maybe is still possible for the baby to 
reach normal thyroid hormone levels at the age of 
more than 14 days, but it could not be concluded yet 
for the growth and development of the baby until the 
first 2 years of his life. 
4. Conclusion 
Management of preconception counselling, 
contraception, and initial screening of patients with a 
history of thyroid carcinoma are the first steps in 
helping the outcome in pregnancies with thyroid 
disorders. Hormone replacement therapy that was 
carried out early and adjusted periodically in 
hypothyroid cases helps to optimize fetal outcomes. 
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